Trial · NCT05271084
Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder
NCT05271084, Phase 1, Phase 2, Completed, Hawler Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder. Trials, record NCT05271084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05271084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder
- NCT number
- NCT05271084
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- Hawler Medical University
- Conditions
- Major Depressive Disorder
- Interventions
- Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg, Citalopram (tablet) 20 mg + Placebo (tablet)
- First posted
- 2022-03-08
- Last updated
- 2022-09-07
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hamilton Depression Rating Scale 17 (HDRS-17) Scores (Time Frame: Baseline, week 2,4,6,8,10, and12) | 12 weeks | The HDRS is a 17-item scale that asks participants to rate the severity of their depression symptoms. Scoring is based on the 17-item scale. The total score ranges from 0 to 52, with higher numbers demonstrating more severe symptoms. Normal scores range from 0 to 7, mild depression ranges from 8 to 16, moderate depression ranges from 17 to 23, and scores of 24 and greater indicate severe depression. Remission is defined as HDRS total score ≤ 7 (primary outcome). |
| Secondary | Effect on the serum level of tumor necrosis factor-alpha (TNF-α) | 12 weeks | Peripheral blood samples will be obtained and serum levels of TNF-α ( pg/mL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of circulating C-reactive protein (CRP) | 12 weeks | Peripheral blood samples will be obtained and serum levels of CRP (mg/dL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of interleukin 6 (IL-6) | 12 weeks | Peripheral blood samples will be obtained and serum levels of IL-6 (pg/mL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of interleukin-1-β (IL-1-β) | 12 weeks | Peripheral blood samples will be obtained and serum levels of IL-1-β (pg/mL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of interleukin-10 (IL-10) | 12 weeks | Peripheral blood samples will be obtained and serum levels of IL-10 (pg/mL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of brain derived neurotrophic factor (BDNF) | 12 weeks | Peripheral blood samples will be obtained and serum levels of BDNF (ng/mL) will be measured at baseline and after treatment (week 12) |
| Secondary | Effect on the serum level of serotonin | 12 weeks | Peripheral blood samples will be obtained and serum levels of serotonin (ng/mL) will be measured at baseline and after treatment (week 12) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05271084
GET https://conductscience.org/api/trials/v1/NCT05271084/registered